Acceleration of Umbilical Cord Blood (UCB) Stem Engraftment: Results of a Phase I Clinical Trial with Stemregenin-1 (SR1) Expansion Culture  by Wagner, John E. et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S48(primarily pre-donation) but better mental health. There was
no main effect difference by data collection time point and no
age by time interaction for physical or mental health.
Despite having somewhat poorer overall general pre-dona-
tion health, older RD experience similar e and in some do-
mains betteredonation-related HRQoL compared to younger
RD. This is a reassuring ﬁnding that supports the use of older
family members as donors and will further inform the
counseling and consent of older RD.28
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Introduction: Allogeneic hematopoietic cell trans-
plantation is effective in patients (pts) with high-riskTable
Characteristic, N ¼ 27 n (%) unless stated
Male gender 16 (59)
Age at dUCBT, median (range) 29 (17-61)
Prior autologous transplant 25 (92.5)
Response prior to dUCBT
Complete Remission 6 (22.2)
Partial Remission 9 (33.3)
Stable Disease 5 (18.5)
Progressive Disease 7 (26)
Conditioning Regimen
Fludarabine/low-dose cyclophosphamide/
TBI 2Gy +/- ATG
10 (37)
Fludarabine/Clofarabine/Busulfan/ATG/
TBI 2 Gy
3 (11)
Fludarabine/Melphalan/ATG 2 (7.5)
Melphalan/Thiotepa/Fludarabine/ATG 12 (44.5)
Total Nucleated Cell Dose (x108/kg) 0.44 (range 0.12-5.94)
HLA match
4/6, 4/6 15 (55.6)
4/6, 5/6 6 (22.2)
5/6, 5/6 5 (18.5)
6/6, 6/6 1 (3.7)
Figure. Left: PFS and overall survival for all patients. Right: Overall survival aclymphoid malignancies including Hodgkin lymphoma (HL).
We studied 27 pts who received double umbilical cord
blood transplant (dUCBT) at The UT M.D. Anderson Cancer
Center or The Royal Melbourne Hospital, Australia for
relapsed/refractory HL.
Patients and Methods: Median number of prior treatments
was 4 (range 2-6); 25 of 27 had had prior autologous trans-
plant. 45% did not achieve at least partial response to their
most recent prior therapy and 26% had progressive disease.
Pts were treated consecutively between Aug 2003 and May
2014. All pts received dUCBT from4/6-6/6matched cord blood
units. Graft versus host disease (GVHD) prophylaxis was
tacrolimus or cyclosporine plus low dose methotrexate or
mycophenolate mofetil. Pts were treated on ex vivo expansion
studies using liquid culture media (N¼8), mesenchymal
stromal cells (N¼3) or fucosylation (N¼3) as available.
Results: Pt and transplant characteristics are described in
Table 1. All pts engrafted. Median time to neutrophil recovery
(ANC> 500/mm3) was 17 days (range: 5-38). Median follow-
up after transplant was 14 months. Cumulative incidences of
grade II acute GVHD and extensive chronic GVHDwere 33.5%
(95% CI 18.8-52.4) and 40.5% (24.7-59.6), respectively. No pt
developed grade III-IV acute GVHD. Sixteen of 27 pts
achieved complete remission (CR) after alloHCT; 7 had
progressive disease at a median time of 7.4 months post-
transplant (range 4.1-36.0). At the time of last follow up 16
of 27 pts were alive. Relapse contributed to death in 3 pts.
The 5-year cumulative incidence of non-relapse mortality
(NRM) was 37.9% (95% CI: 20.9-59.0). Five year probabilities
of progression free-survival (PFS), and overall survival (OS)
were 31.3 (95% CI: 15.0-54.0) and 47.9 (95% CI: 26.2-70.5),
respectively (Figure). Small numbers limited the ability to
deﬁne prognostic factors; however there was a trend
toward inferior survival in pts achieving less than PR to
their most recent prior treatment (p¼0.12).
Conclusions: dUCBT is effective for patients with advanced
HL. Relapse rate was low and approximately 30% of pts
achieve long-term disease-free survival, including pts with
chemorefractory disease prior to dUCBT.29
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UCB has been substantially limited by the low ﬁnite number
of CD34+ cells, resulting in slow hematopoietic recovery and
poor engraftment. SR1 is an aryl hydrocarbon receptor
antagonist that enables CD34 cell proliferation in the pres-
ence of SCF, Flt-3L, IL-6 and TPO. Therefore, we tested the
safety and efﬁcacy SR1-expanded UCB (referred to as
‘HSC835’). Nineteen patients (pts) with high-risk hemato-
logic malignancy have been treated with HSC835 after
myeloablative conditioning (cyclophosphamide 120 mg/kg,
ﬂudarabine 75 mg/m2 and TBI 1320 cGy) with CsA and MMF
post-transplant immune suppression. The ﬁrst 17 received
an unmanipulated second ‘back-up’ UCB unit. SR-1 expan-
sion culture yielded a median of 1,440 x 106 CD34+ cells
(range, 140.2-6361.9), a 328-fold (range, 65.9-844.0) expan-
sion of CD34+ cells, for a median infused dose of 12.3 x 106
CD34+ cells/kg (2.3-48.5). As shown (Figure), all patients
engrafted with the HSC835 unit predominating in 11/17 at a
median of 11 days for neutrophils (6-23). As expected, unit
predominance was determined by graft-graft immune re-
actions, as evidenced by the presence of interferon-g pro-
ducing T cells directed against the losing graft. Chimerism in
HSC835 engrafted patients was stable long term with no
episode of late graft failure. Compared to 111 identically
treated DUCB transplant historical controls withoutFigure. Hematopoietic Recovery Panels A and B: Rate of neutrophil and platelet rec
Comparison of CD34 cell dose and days to neutrophil recovery segregated by SR-1
transplanted with SR1 plus a companion UMN UCB unit () and those with SR-1 UCBexpanded cells (conventional arm), neutrophil and platelet
recovery was remarkably shortened in HSC835 recipients
(p<0.001 and p¼0.001, respectively). Based on these data, a
second trial with HSC835 as a stand-alone graft was initiated.
In two patients, receiving 25 and 18 x 106 CD34/kg, neutro-
phil recovery was rapid (days 12 and 8, respectively) and
complete (100% chimerism). In summary, HSC835 dramati-
cally accelerates hematopoietic recovery, abrogating the
principal barrier to the successful use of UCB. Such impres-
sive CD34+ expansion may lead to a paradigm shift for both
UCB transplantation and banking.
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A phase 3 randomized trial of transplantation of bone
marrow (BM) versus peripheral-blood (PB) stem cells from
unrelated donors showed no signiﬁcant (sig) differencesovery compared to double UCB transplant historical controls. Panels C and D:
versus unmanipulated (UMN) unit predominance. Symbols indicate patients
as a ‘stand alone’ graft (:).
